Wilson's disease(WD)
Conditions
Interventions
Phase I: Experimental,LY-M003 Dose group 1:Participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 1.Dose group 1 (4.0 x 10^13 vg/kg)
Phase I: Experimental,LY-M003 de-escalation dose :Phase I: Subjects receive a single peripheral intravenous infusion of LY-M003 at a de-escalation dose, de-escalation dose group (2.0 × 10^13 vg/kg)
Phase II: Experimental,LY-M003 Dose group 1:Phase II:Participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 1. Dose group 1 (4.0 × 10^13 vg/kg)
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged = 18 and = 60 years, regardless of gender. 2. The subject fully comprehends the purpose, design, methods and possible adverse events of the study, agrees to participate voluntarily and signs the informed consent form (ICF). 3. Patients with confirmed diagnosis of Wilson's disease (WD). 4. Subjects with Wilson's disease (WD) confirmed by laboratory testing to have biallelic ATP7B gene mutation or deletion. 5. The subjects are treated patients with Wilson's disease (WD) who have received standard therapy (e.g., D-penicillamine or zinc acetate) continuously for at least 6 months prior to screening. 6. Subjects have maintained a low-copper diet for at least 6 consecutive months prior to screening and will continue this dietary restriction throughout the study. 7. Subjects must agree to refrain from donating blood, organs, tissues or cells at any time after treatment. 8. Female subjects of childbearing potential (WOCBP) must have a negative pregnancy test. 9. Subjects and their partners must have no plans for pregnancy from screening through 6 months after study completion, and will voluntarily use effective contraception (e.g., abstinence, condoms). Subjects shall not plan to donate sperm or ova.
Exclusion criteria
Exclusion criteria: 1. AAV8 neutralizing antibody titer > 1:10 . 2. History of active gastrointestinal bleeding within the past 3 months. 3. Decompensated liver cirrhosis or advanced liver disease presenting with portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, etc. 4. Subjects with other concomitant liver diseases as judged by the investigator, including autoimmune hepatitis, alcoholic liver disease, primary biliary cholangitis, primary sclerosing cholangitis, and/or drug- or toxin-induced liver disease. 5. Subjects with severe hypersplenism complicated and requiring splenectomy as assessed by the investigator. 6. Model for End-Stage Liver Disease (MELD) score > 13. 7. Other disorders of copper metabolism, such as chronic cholestatic liver diseases, disorders of glycosylation, copper metabolism disorders, etc. 8. A history of non-compliance with copper chelators or zinc agents as assessed by the investigator within 6 months prior to screening. 9. Previously treated WD subjects with ALT and/or AST levels more than 5 times the upper limit of normal (ULN). 10.Subjects with severe neurological deficits or impairments that, in the investigator’s judgment, compromise their safety and/or ability to participate in the study. 11. Hemoglobin 1000 mg/dL); 15. Subjects who have received or plan to undergo bone marrow transplantation, hematopoietic stem cell transplantation and/or major organ transplantation, including but not limited to liver transplantation and renal transplantation. 16. Subjects with clinically diagnosed severe cardiovascular diseases or those deemed by the investigator to have such conditions (e.g., New York Heart Association [NYHA] heart failure classification = Class 3). 17.Subjects with uncontrolled concomitant diseases or infectious diseases as assessed by the investigator. 18. Subjects who are allergic to any ingredient of LY-M003 Injection. 19. Prior receipt of any type of gene therapy or cell therapy. 20. Use of systemic immunosuppressants or steroids within 3 months prior to administration (except for prophylactic immunosuppressive therapy specified in the protocol). 21. History of cancer within 5 years prior to screening, excluding completely resected non-melanoma skin cancer, non-metastatic prostate cancer and fully cured ductal carcinoma in situ. 22. Received live attenuated vaccines within 4 months prior to screening, or planned to receive such vaccines during the clinical trial. 23. Received treatment or intervention with other investigational drugs or study devices within 28 days or 5 half-lives (for drugs only) prior to screening, whichever is longer. 24. Pregnant women (or women planning pregnancy) or breastfeeding women. 25. Other conditions that, in the investigator’s opinion, render the subject ineligible for study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase I:The incidence of dose-limiting toxicity (DLT) events adjudicated by the Safety Review Committee (SRC) within at least 28 days after LY-M003 infusion.;Phase I/II: The incidence of treatment-emergent adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs) related to LY-M003 within 52 weeks after infusion; and the incidence of abnormal findings in 12-lead ECG, vital signs (blood pressure, pulse, respiratory rate, body temperature), laboratory tests (blood routine, blood biochemistry, coagulation function, stool routine, urine routine) and physical examinations within 52 weeks after administration.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Phase I/II: Percentage reduction in the dosage of standard of care (SoC) medications within 52 weeks after administration.;Phase I/II: Number and proportion of subjects who discontinued standard of care (SoC) medications within 52 weeks after administration.;Phase I/II: Duration (in treatment weeks) of consecutive discontinuation of SoC medications among the above subjects.;Phase I/II: Change in serum non-caeruloplasmin-bound copper (NCC) from baseline within 52 weeks after administration;Phase I/II: Change in serum ceruloplasmin level from baseline within 52 weeks after administration;Phase I/II:Change in serum ceruloplasmin activity level from baseline within 52 weeks after administration;Phase I/II:Change in 24-hour urinary copper content from baseline at each follow-up time point within 52 weeks after administration;Phase I/II:Change in serum total copper from baseline within 52 weeks after administration;Phase I/II:Change from baseline in total score of the neurological subscale of the Unified Wilson's Disease Rating Scale (UWDRS) within 52 weeks after administration;Phase I/II:Change from baseline in liver function subscale score of the Unified Wilson's Disease Rating Scale (UWDRS) within 52 weeks after administration;Phase I/II:Change from baseline in psychiatric subscale score of the Unified Wilson's Disease Rating Scale (UWDRS) within 52 weeks after administration;Phase I/II:Change from baseline in individual item/subscale scores (speech, handwriting, standing and gait) of the Unified Wilson's Disease Rating Scale (UWDRS) within 52 weeks after administration;Phase I/II:Change in ALT and AST from baseline within 52 weeks after administration;Phase I/II:Change in liver stiffness from baseline within 52 weeks after administration;Phase I/II:Change in Kayser-Fleischer (K-F) rings from baseline within 52 weeks after administration;Phase I/II:Distribution and shedding of AAV8 in blood, saliva, urine and feces;Phase I/II:Development of anti-drug antibodies (ADA) a | — |
Countries
China
Contacts
Public ContactChaohui Yu
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed